Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced the presentation of preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), at the 2022 ACAAI Annual Scientific Meeting in Louisville, Kentucky. The e-poster, titled "Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215," will be presented by Jou-Ku Chung on November 13, 2022 at 12:05 PM ET. STAR-0215 aims for long-lasting prevention of HAE attacks with dosing every three months. The ongoing Phase 1a clinical trial's preliminary results are expected by year-end.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share preclinical data for STAR-0215 in a presentation titled “Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215” at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky.

The e-poster will be presented by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics, on Sunday, November 13, 2022 at 12:05pm ET, and will be available to all registrants through the ACAAI ePoster Live System for the duration of the meeting and for six months following the meeting.

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer. The company’s goal is to provide the most patient-friendly preventative treatment option for people living with HAE. Astria’s Phase 1a clinical trial of STAR-0215 in healthy subjects is ongoing, with preliminary results anticipated by year-end.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the Company’s expectations regarding the timing of preliminary results from the STAR-0215 Phase 1 clinical trial ; the potential attributes and differentiated profile of STAR-0215 as a potential treatment for HAE, including potential dosing of every three months or longer and the Company’s goal of providing the most patient-friendly preventative treatment option for people living with HAE; and the Company’s mission to bring life changing therapies to patients and families affected by rare and niche allergic and immunological diseases. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Company’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties: changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including the COVID-19 pandemic; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of pre-clinical studies may not be replicated in clinical studies, the Company’s ability to enroll patients in our clinical trials, and the risk that any of the Company’s clinical trials may not commence, continue or be completed on time, or at all; decisions made by, or feedback received from, the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and other review bodies with respect to STAR-0215 and any future product candidates; the Company’s ability to manufacture sufficient quantities of drug substance and drug product on a cost-effective and timely basis; the Company’s ability to obtain, maintain and enforce intellectual property rights for STAR-0215 and any other future product candidates; competition; the Company’s ability to manage its cash usage and the possibility of unexpected cash expenditures; the Company’s ability to obtain necessary financing to conduct its planned activities and to manage unplanned cash requirements; general economic and market conditions; as well as the risks and uncertainties set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. The Company may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on the Company’s forward-looking statements. Neither the Company, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005118/en/

Astria:



Investor relations:

Andrea Matthews

investors@astriatx.com



Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is STAR-0215 and its significance for Astria Therapeutics (ATXS)?

STAR-0215 is a monoclonal antibody treatment developed by Astria Therapeutics (ATXS) for preventing attacks of hereditary angioedema (HAE), with the potential for long-acting dosing every three months.

When will Astria Therapeutics present data on STAR-0215?

Astria Therapeutics will present an e-poster on STAR-0215 on November 13, 2022, at 12:05 PM ET during the 2022 ACAAI Annual Scientific Meeting.

What type of meeting will Astria Therapeutics (ATXS) present at?

Astria Therapeutics (ATXS) will present at the 2022 ACAAI Annual Scientific Meeting held in Louisville, Kentucky.

When are the preliminary results for STAR-0215 expected?

Preliminary results from the Phase 1a clinical trial of STAR-0215 by Astria Therapeutics are anticipated by the end of this year.

Who is presenting the e-poster on STAR-0215 for Astria Therapeutics?

The e-poster on STAR-0215 will be presented by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics.